Patients Walk Away From Expensive Drugs, Get Sicker

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A study by medical industry research firm Wolters Kluwer Pharma Solutions reported on in The Wall Street Journal, says that people who order prescription drugs often do not pick them up at pharmacies because they find then to be too expensive. It is a wonder that the people who need these drugs do not check what they will cost ahead of time, but many people do not read their cellphone subscription plans and later complain of high bills.

The paper reports that “nearly one in 10 new prescriptions for brand-name drugs were abandoned by people with commercial health plans in the quarter, up 88% from four years earlier, when the data were first tracked and before the recession began.”

Leaving aside the fact that people even those with health insurance do not believe that they can afford drugs that they need, it would seem to be a basic premise of health care reform that health care should be more affordable. That is not the case, and big pharma companies still appear to make large profits, perhaps too large, on their products. Whatever programs the Administration and Congress have put into place have not frightened drug companies enough for them to change old habits.

The free market view of drug prices is that phama companies should charge what they believe is the most profitable price for any treatment. What they lose in customers who cannot pay for their products, they make up in high prices. The government has already decided that the nation cannot afford those practices.  Pharma companies may believe that the government cannot track every transaction.

When drug prices are inelastic, some people who need them are bound to walk away and become sicker than if they took their medications. These people put a burden on the health care system because they are often treated in hospitals for conditions that could have been managed more cheaply by doctors in their offices or at local clinics.

So, the government has a plan in place that has not worked yet, and the pharma companies do not appear to be worried about conditions that may eventually bring their profits down. Make money now — they must reason–no matter who gets sick.

Douglas A. McIntyre

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618